×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LPTX – leap therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LPTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
01:27 pm
lptx
Leap Therapeutics (NASDAQ:LPTX) is now covered by analysts at Weiss Ratings. They set a "sell (e+)" rating on the stock.
Neutral
Report
Leap Therapeutics (NASDAQ:LPTX) is now covered by analysts at Weiss Ratings. They set a "sell (e+)" rating on the stock.
11/13
09:18 am
lptx
Solana in the Shade: Crypto Daybook Americas [Yahoo! Finance]
Neutral
Report
Solana in the Shade: Crypto Daybook Americas [Yahoo! Finance]
11/12
10:48 pm
lptx
Will Winklevoss Twins Successfully Takeover ZCash? [Yahoo! Finance]
Neutral
Report
Will Winklevoss Twins Successfully Takeover ZCash? [Yahoo! Finance]
11/12
06:11 pm
lptx
Winklevoss-backed stock halted multiple times after wild 550% rally [Yahoo! Finance]
High
Report
Winklevoss-backed stock halted multiple times after wild 550% rally [Yahoo! Finance]
11/12
10:41 am
lptx
BC-Most Active Stocks [Yahoo! Finance]
High
Report
BC-Most Active Stocks [Yahoo! Finance]
11/12
09:27 am
lptx
Cypherpunk Technologies GAAP EPS of -$0.08 [Seeking Alpha]
High
Report
Cypherpunk Technologies GAAP EPS of -$0.08 [Seeking Alpha]
11/12
08:00 am
lptx
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
High
Report
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
11/12
08:00 am
lptx
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
High
Report
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
04:11 pm
lptx
Form DEFA14A LEAP THERAPEUTICS, INC.
High
Report
Form DEFA14A LEAP THERAPEUTICS, INC.
11/12
04:08 pm
lptx
Form 8-K LEAP THERAPEUTICS, INC. For: Nov 12
High
Report
Form 8-K LEAP THERAPEUTICS, INC. For: Nov 12
11/12
09:14 am
lptx
Form 424B5 LEAP THERAPEUTICS, INC.
High
Report
Form 424B5 LEAP THERAPEUTICS, INC.
11/12
08:15 am
lptx
Form 10-Q LEAP THERAPEUTICS, INC. For: Sep 30
High
Report
Form 10-Q LEAP THERAPEUTICS, INC. For: Sep 30
11/12
08:10 am
lptx
Form 8-K LEAP THERAPEUTICS, INC. For: Nov 11
High
Report
Form 8-K LEAP THERAPEUTICS, INC. For: Nov 11
11/3
08:45 am
lptx
Form DEFA14A LEAP THERAPEUTICS, INC.
Medium
Report
Form DEFA14A LEAP THERAPEUTICS, INC.
11/3
08:40 am
lptx
Form DEF 14A LEAP THERAPEUTICS, INC. For: Dec 15
Medium
Report
Form DEF 14A LEAP THERAPEUTICS, INC. For: Dec 15
10/24
04:58 pm
lptx
Form PRE 14A LEAP THERAPEUTICS, INC. For: Dec 15
Low
Report
Form PRE 14A LEAP THERAPEUTICS, INC. For: Dec 15
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/3
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
51.9%
1/4 Leap Therapeutics Inc (NASDAQ: LPTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 20.6%
2/26 Leap Therapeutics to Present at Cowen 40th Annual Health Care Conference 15.0%
3/23 Form 3 LEAP THERAPEUTICS, INC. For: Mar 12 Filed by: BeiGene, Ltd. 14.5%
4/20 Form SC 13G LEAP THERAPEUTICS, INC. Filed by: PERCEPTIVE ADVISORS LLC 13.8%
3/18 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 17 12.8%
4/23 Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers 12.2%
1/23 Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting 11.7%
6/12 Form 4 LEAP THERAPEUTICS, INC. For: Jun 11 Filed by: LAWLOR AUGUSTINE 10.3%
3/17 Leap Therapeutics Inc (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock. 8.4%
1/4 Leap Therapeutics Inc (NASDAQ: LPTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 20.6%
2/26 Leap Therapeutics to Present at Cowen 40th Annual Health Care Conference 15.0%
3/23 Form 3 LEAP THERAPEUTICS, INC. For: Mar 12 Filed by: BeiGene, Ltd. 14.5%
4/20 Form SC 13G LEAP THERAPEUTICS, INC. Filed by: PERCEPTIVE ADVISORS LLC 13.8%
3/18 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 17 12.8%
4/23 Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers 12.2%
1/23 Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting 11.7%
6/12 Form 4 LEAP THERAPEUTICS, INC. For: Jun 11 Filed by: LAWLOR AUGUSTINE 10.3%
3/17 Leap Therapeutics Inc (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock. 8.4%
TOP News Decliners
11/14
Q3/2019 9/30/2019 EPS -0.330 ZacksConsensus -0.330 ActVsEst 0.000 - In-Line
-53.6%
8/6 Form 8-K LEAP THERAPEUTICS, INC. For: Aug 06 -23.0%
3/18 Leap Therapeutics Announces Executive Leadership Changes -19.3%
9/17 Form 8-K LEAP THERAPEUTICS, INC. For: Sep 16 -18.3%
3/16 Form 10-K LEAP THERAPEUTICS, INC. For: Dec 31 -12.2%
7/11 Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital -7.9%
2/1 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.6%
3/4 Form 4 LEAP THERAPEUTICS, INC. For: Mar 02 Filed by: LITTLECHILD JOHN W -7.1%
3/9 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 05 -6.4%
6/5 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
8/6 Form 8-K LEAP THERAPEUTICS, INC. For: Aug 06 -23.0%
3/18 Leap Therapeutics Announces Executive Leadership Changes -19.3%
9/17 Form 8-K LEAP THERAPEUTICS, INC. For: Sep 16 -18.3%
3/16 Form 10-K LEAP THERAPEUTICS, INC. For: Dec 31 -12.2%
7/11 Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital -7.9%
2/1 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.6%
3/4 Form 4 LEAP THERAPEUTICS, INC. For: Mar 02 Filed by: LITTLECHILD JOHN W -7.1%
3/9 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 05 -6.4%
6/5 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: